Mechanisms of adverse effects of anti-VEGF therapy for cancer. - Wikidata - wikimedia - TriplyDB

Mechanisms of adverse effects of anti-VEGF therapy for cancer.

Mechanisms of adverse effects of anti-VEGF therapy for cancer.

http://www.wikidata.org/entity/Q36609627

about

Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib Guidance molecules in lung cancer Modes of resistance to anti-angiogenic therapy The Role of RhoJ in Endothelial Cell Biology and Tumor Pathology Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives Selective use of sorafenib in the treatment of thyroid cancer Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib Pharmacologic resistance in colorectal cancer: a review The Crossroads of Geriatric Cardiology and Cardio-Oncology Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials Nanoemulsions in translational research-opportunities and challenges in targeted cancer therapy Targeting angiogenesis in squamous non-small cell lung cancer Microvascular repair: post-angiogenesis vascular dynamics Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis r84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity induction Cancer and liver cirrhosis: implications on prognosis and management Adaptation to antiangiogenic therapy in neurological tumors Quercetin-4'-O-β-D-glucopyranoside (QODG) inhibits angiogenesis by suppressing VEGFR2-mediated signaling in zebrafish and endothelial cells The HILDA complex coordinates a conditional switch in the 3'-untranslated region of the VEGFA mRNA Anti-cancer activity of an osthole derivative, NBM-T-BMX-OS01: targeting vascular endothelial growth factor receptor signaling and angiogenesis The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial Cells A role for a CXCR2/phosphatidylinositol 3-kinase gamma signaling axis in acute and chronic vascular permeability.Identification of novel targets for antiangiogenic therapy by comparing the gene expressions of tumor and normal endothelial cells Increased Wnt5a in squamous cell lung carcinoma inhibits endothelial cell motility Mo polyoxometalate nanoparticles inhibit tumor growth and vascular endothelial growth factor induced angiogenesis Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials.Incidence and risk of hypertension associated with cabozantinib in cancer patients: a systematic review and meta-analysis.Cancer drug related cardiotoxicity during breast cancer treatment.Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant.Angiogenic inhibition in high-grade gliomas: past, present and future.Designing a broad-spectrum integrative approach for cancer prevention and treatment.Circulating tumor cell data: integration with imaging and serum tumor markers for metastatic breast cancer patient management.Off-target platelet activation in macaques unique to a therapeutic monoclonal antibody.Ponatinib reduces viability, migration, and functionality of human endothelial cells.Unexpected thrombocytopenia and anemia in cynomolgus monkeys induced by a therapeutic human monoclonal antibody.Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy.Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis.

P2860

Q21261282-BC1A3C12-7671-4771-ABBA-E5331ADA93CE Q24598659-BCAD7AA9-2CF0-4F3C-89B7-FA0F5813C57F Q24608005-AD1927DE-F5A8-453B-B24D-DBA10523303A Q26739169-7D454585-7865-4337-B3F0-164D900AE34A Q26751280-69195507-630E-4266-944F-4A692F9EF220 Q26752891-E935F2D5-588E-4AB1-8236-A33C728534DB Q26765210-06649374-475F-4EF0-AB24-21C13CA566C0 Q26769850-7D6204D3-156F-4095-ACD1-3B00D9CB17C5 Q26778666-C2214C7C-5E93-484E-AA9E-7DB8D8722EC0 Q26822790-09DA88F8-44B7-49ED-B483-ABF72C60545C Q26858849-4188C395-2104-4323-98B2-2E79FF33EC10 Q26861341-B2B5A55C-DE8D-4087-9F84-03EAB09C76AD Q27004093-1BB6EA7D-E3AA-4730-8A04-CE0BDFBBEC2C Q27004170-F4ECB76E-E57C-48E8-9332-11AFE00ECED0 Q27026453-8F4A7E56-C7D4-42A8-9D6B-DD5E0F50B587 Q27321768-7949355C-A424-4C50-B07C-B91C25B3E924 Q28068579-508C745B-C347-45BF-A337-17E29E61303C Q28082908-3B137181-11B4-426A-9890-2601C80DD495 Q28480617-06E287B0-37E2-4A48-B8DB-6955E927E129 Q28535448-A943640E-7294-4787-B276-49FAEAE0590D Q28535457-3B59D4B4-D659-4DC0-9318-4260B5F3E3F1 Q28550616-4D5C17A1-1F53-4497-9393-A3E0D7B6ADF2 Q28566820-A73301C4-1429-4D67-8B7F-F5B9B44D99DE Q28650438-2759824F-51BD-4F6C-B9D4-6FA4AEB353F7 Q28820722-1A7467A1-DD3D-47EE-91BC-E66EDDCD5639 Q28822397-C2DA7478-F5CC-4FA3-8183-48C4CE91C4D1 Q30248296-FAB4B604-DFF8-4877-9C16-76579822A686 Q30250303-3532D93A-83FF-4CE0-8C8B-8BE3848352B9 Q30251498-09CF0B74-D1A6-452C-8F9D-14D8DC1D86CE Q30364937-44C9C0D2-56FD-439F-97FE-2D1420305ECF Q30453939-69C04714-5560-4121-B8B1-23E605D69909 Q30455596-6690B790-A066-4500-8F0D-C78A86B253CE Q30736359-651695C2-D698-477F-B253-B2B61D6B1F67 Q30815483-0F9D4C80-0BA8-475E-95FB-C78B4298A8F0 Q33161260-347A6F48-72C2-498B-986A-52D461665649 Q33364077-2BA6EFC3-21AD-4354-A1B2-BE1582C1E428 Q33406359-54C4C07F-866F-4C5D-806B-FE8ADE78B29E Q33410375-01379594-2CB7-4874-B42A-4F1243D5E445 Q33423350-62C5B961-752B-41B2-97EB-DF35026CAEBE Q33426343-4AD37091-40E3-447D-A261-A6463536A4EC

P2860

Mechanisms of adverse effects of anti-VEGF therapy for cancer.

http://www.wikidata.org/entity/Q36609627

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Mechanisms of adverse effects of anti-VEGF therapy for cancer.

@ast

Mechanisms of adverse effects of anti-VEGF therapy for cancer.

@en

type

label

Mechanisms of adverse effects of anti-VEGF therapy for cancer.

@ast

Mechanisms of adverse effects of anti-VEGF therapy for cancer.

@en

prefLabel

Mechanisms of adverse effects of anti-VEGF therapy for cancer.

@ast

Mechanisms of adverse effects of anti-VEGF therapy for cancer.

@en

P1433

Q36609627-0E292123-07F5-4D44-8B5D-9BE4E20E525A

P1476

Q36609627-1D4DA0DB-D165-4418-9119-8DD12C943644

P2093

Q36609627-47A02C31-005B-4534-A0D4-D8F4661D5668

Q36609627-D7FAB6BF-359F-4736-8BD6-3195D8393BD9

P2860

Q36609627-0287372D-AA0C-492A-A05E-B5ADDC5AE8B9

Q36609627-040C9FE1-28C1-43FA-83CB-E6236DBAC35C

Q36609627-08B6B16B-DC37-4FFE-B4C7-0D30D5BD5BDF

Q36609627-09A8F2E3-217F-40A4-9980-20E58CF2635A

Q36609627-2D6B8299-EB8F-48C3-B404-A114059908DB

Q36609627-2ED51E7D-812E-408D-8075-5F8141553870

Q36609627-4BB9E6DF-A9D3-4348-A519-E987B51BCE11

Q36609627-4BC3020D-C85B-433F-A79A-550E6AA9263E

Q36609627-4DE072E7-5CF9-4352-A3C2-A37E67FA9EF5

Q36609627-5343BAFC-4A2B-4CAD-A1AE-18E890A1A560

P2888

Q36609627-E049A5CA-BA32-4321-B6E6-EB452810CF72

P304

Q36609627-DD3557DF-7202-4173-AF67-B94E91FF1061

P31

Q36609627-33F0738A-6F4E-452B-9D8A-CD92C1453874

Q36609627-8A7B769E-FABC-4A09-BAA2-4626A112CC90

P356

Q36609627-E44A487B-EC69-4DAA-B655-673D1D1F4C41

P407

Q36609627-E5F07655-09A7-4A22-BB25-35FBA4160BEB

P433

Q36609627-CA44E34A-0573-43EE-A847-3474672E88BE

P478

Q36609627-9F7EB125-0F93-43AE-B3BF-D4B17687F90D

P577

Q36609627-32CB739A-191A-4021-85E5-077CE08B32D9

Q36609627-F0626EB7-E126-458E-A350-ABFB97A06204

P5875

Q36609627-1B1CEF89-A850-491E-9B72-7E7C6CC389E8

P698

Q36609627-0949F12C-891F-4F34-9F90-088879898BDB

P921

Q36609627-2609FAE4-C565-49DA-98FD-DE64B9FB86E8

Q36609627-2D677EC8-46EE-404A-B417-F8FB0BF09244

P932

Q36609627-F9C8E03E-266E-48B3-AB8C-86954656FED5

P356

P1433

British Journal of Cancer

P1476

Mechanisms of adverse effects of anti-VEGF therapy for cancer.

@en

P2093

D M McDonald

http://www.w3.org/2001/XMLSchema#string

T Kamba

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor angiogenesis: therapeutic implications

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Sorafenib in advanced clear-cell renal-cell carcinoma

The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice.

Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.

Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor.

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

VEGF at the neurovascular interface: therapeutic implications for motor neuron disease.

P2888

P304

1788-1795

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6603813

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P577

2007-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2007-06-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6312647

http://www.w3.org/2001/XMLSchema#string

P698

17519900

http://www.w3.org/2001/XMLSchema#string

P921

P932

2359962

http://www.w3.org/2001/XMLSchema#string